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1. INTRODUCTION {#brb31132-sec-0005}
===============

Parkinson\'s disease (PD) is the second most common neurodegenerative diseases worldwide (de Lau & Breteler, [2006](#brb31132-bib-0012){ref-type="ref"}) affecting about 6.2 million people globally in 2015 (Collaborators GMaCoD, [2016](#brb31132-bib-0010){ref-type="ref"}). Motor dysfunction of PD is mainly manifested as resting tremors, rigidity, bradykinesia, and postural instability (Jankovic, [2008](#brb31132-bib-0025){ref-type="ref"}). The loss of presynaptic nigrostriatal dopamine neurons and a progressive nigrostriatal dopamine deficiency in the cortico‐striato‐thalamocortical circuit is considered the primary mechanism of motor dysfunction of PD (Wichmann, DeLong, Guridi, & Obeso, [2011](#brb31132-bib-0056){ref-type="ref"}). Many therapeutic approaches have been developed for the treatment of PD.

Repetitive transcranial magnetic stimulation (rTMS), by its ability to modulate cortical excitability, is a safe and noninvasive therapy that has been widely used for the treatment of neurological and psychiatric disorders including stroke, Alzheimer\'s disease, depression, and PD (Chen et al., [2014](#brb31132-bib-0006){ref-type="ref"}; Hsu, Cheng, Liao, Lee, & Lin, [2012](#brb31132-bib-0023){ref-type="ref"}; Liao et al., [2015](#brb31132-bib-0035){ref-type="ref"}). High‐frequency rTMS (HF‐rTMS) (\>1.0 Hz) can enhance the cortical excitability whereas low‐frequency (≤1.0 Hz) rTMS (LF‐rTMS) can decrease the cortical excitability (Maeda, Keenan, Tormos, Topka, & Pascual‐Leone, [2000](#brb31132-bib-0037){ref-type="ref"}; Peinemann et al., [2004](#brb31132-bib-0043){ref-type="ref"}). Theta burst stimulation (TBS) is another form of rTMS protocol with a high‐frequency and low‐intensity stimulation. Intermittent theta burst stimulation (iTBS) enhances cortical excitability, whereas continuous theta stimulation (cTBS) decreases cortical excitability (Huang, Edwards, Rounis, Bhatia, & Rothwell, [2005](#brb31132-bib-0024){ref-type="ref"}). Except for the direct impact on the cortical excitability of the stimulated site, rTMS can also influence the excitability of other brain regions related to the stimulation site probably through the cortico‐striato‐thalamocortical circuit (Gonzalez‐Garcia et al., [2011](#brb31132-bib-0020){ref-type="ref"}; Strafella, Paus, Barrett, & Dagher, [2001](#brb31132-bib-0052){ref-type="ref"}). Therefore, many studies have been undertaken to investigate the effectiveness of rTMS for PD patients with motor dysfunction.

Recent reviews Chou, Hickey, Sundman, Song, and Chen ([2015](#brb31132-bib-0007){ref-type="ref"}), Zanjani, Zakzanis, Daskalakis, and Chen ([2015](#brb31132-bib-0058){ref-type="ref"}) and Zhu et al. ([2015](#brb31132-bib-0059){ref-type="ref"}) show the therapeutic effects of rTMS on motor dysfunction of PD patients as evaluated with the motor section of the Unified Parkinson\'s Disease Rating Scale (UPDRS‐III) and the optimal parameters of rTMS on the functional motor improvement of PD. Optimal parameters, however, have yet to be established. For example, many studies used rTMS protocols varying in stimulation parameters such as (a) stimulation sites of primary motor cortex (M1; Benninger et al., [2012](#brb31132-bib-0002){ref-type="ref"}; Bornke, Schulte, Przuntek, & Muller, [2004](#brb31132-bib-0003){ref-type="ref"}; Brys et al., [2016](#brb31132-bib-0005){ref-type="ref"}; Filipovic, Rothwell, van de Warrenburg, & Bhatia, [2009](#brb31132-bib-0017){ref-type="ref"}; Flamez et al., [2016](#brb31132-bib-0018){ref-type="ref"}; Khedr, Farweez, & Islam, [2003](#brb31132-bib-0027){ref-type="ref"}; Khedr, Rothwell, Shawky, Ahmed, & Hamdy, [2006](#brb31132-bib-0028){ref-type="ref"}; Kim et al., [2015](#brb31132-bib-0029){ref-type="ref"}; Lefaucheur et al., [2004](#brb31132-bib-0032){ref-type="ref"}; Maruo et al., [2013](#brb31132-bib-0038){ref-type="ref"}; Okabe, Ugawa, & Kanazawa, [2003](#brb31132-bib-0042){ref-type="ref"}; Siebner, Rossmeier, Mentschel, Peinemann, & Conrad, [2000](#brb31132-bib-0051){ref-type="ref"}; Yokoe et al., [2018](#brb31132-bib-0057){ref-type="ref"}) supplementary motor area (SMA; Brusa et al., [2006](#brb31132-bib-0004){ref-type="ref"}; Eggers, Günther, Rothwell, Timmermann, & Ruge, [2015](#brb31132-bib-0015){ref-type="ref"}; Hamada, Ugawa, & Tsuji, [2008](#brb31132-bib-0021){ref-type="ref"}; Koch et al., [2005](#brb31132-bib-0031){ref-type="ref"}; Shirota, Ohtsu, Hamada, Enomoto, & Ugawa, [2013](#brb31132-bib-0050){ref-type="ref"}; Yokoe et al., [2018](#brb31132-bib-0057){ref-type="ref"}) dorsal lateral prefrontal cortex (DLPFC; Brys et al., [2016](#brb31132-bib-0005){ref-type="ref"}; del Olmo, Bello, & Cudeiro, [2007](#brb31132-bib-0013){ref-type="ref"}; Nardone et al., [2014](#brb31132-bib-0041){ref-type="ref"}; Sedlackova, Rektorova, Srovnalova, & Rektor, [2009](#brb31132-bib-0049){ref-type="ref"}; Yokoe et al., [2018](#brb31132-bib-0057){ref-type="ref"}) the dorsal premotor (PMD; Sedlackova et al., [2009](#brb31132-bib-0049){ref-type="ref"}) and M1+ DLPFC (The M1+ DLPFC stimulation was considered as complex region stimulation; Benninger et al., [2011](#brb31132-bib-0001){ref-type="ref"}; Brys et al., [2016](#brb31132-bib-0005){ref-type="ref"}; Lomarev et al., [2006](#brb31132-bib-0036){ref-type="ref"};) (b) LF‐rTMS (from 0.2 Hz to 1.0 Hz; Brusa et al., [2006](#brb31132-bib-0004){ref-type="ref"}; Filipovic et al., [2009](#brb31132-bib-0017){ref-type="ref"}; Flamez et al., [2016](#brb31132-bib-0018){ref-type="ref"}; Koch et al., [2005](#brb31132-bib-0031){ref-type="ref"}; Lefaucheur et al., [2004](#brb31132-bib-0032){ref-type="ref"}; Nardone et al., [2014](#brb31132-bib-0041){ref-type="ref"}; Okabe et al., [2003](#brb31132-bib-0042){ref-type="ref"}; Shirota et al., [2013](#brb31132-bib-0050){ref-type="ref"}) or HF‐rTMS (5.0 Hz: Hamada et al., [2008](#brb31132-bib-0021){ref-type="ref"}; Khedr et al., [2003](#brb31132-bib-0027){ref-type="ref"}; Koch et al., [2005](#brb31132-bib-0031){ref-type="ref"}; Siebner et al., [2000](#brb31132-bib-0051){ref-type="ref"}, 10.0 Hz: Bornke et al., [2004](#brb31132-bib-0003){ref-type="ref"}; Brys et al., [2016](#brb31132-bib-0005){ref-type="ref"}; del Olmo et al., [2007](#brb31132-bib-0013){ref-type="ref"}; Khedr et al., [2006](#brb31132-bib-0028){ref-type="ref"}; Kim et al., [2015](#brb31132-bib-0029){ref-type="ref"}; Lefaucheur et al., [2004](#brb31132-bib-0032){ref-type="ref"}; Maruo et al., [2013](#brb31132-bib-0038){ref-type="ref"}; Shirota et al., [2013](#brb31132-bib-0050){ref-type="ref"}; Sedlackova et al., [2009](#brb31132-bib-0049){ref-type="ref"}; Yokoe et al., [2018](#brb31132-bib-0057){ref-type="ref"}, 25.0 Hz: Lomarev et al., [2006](#brb31132-bib-0036){ref-type="ref"} and 50.0 Hz: Benninger et al., [2012](#brb31132-bib-0002){ref-type="ref"}); (c) rTMS sessions: (one session: Bornke et al., [2004](#brb31132-bib-0003){ref-type="ref"}; Brusa et al., [2006](#brb31132-bib-0004){ref-type="ref"}; Eggers et al., [2015](#brb31132-bib-0015){ref-type="ref"}; Flamez et al., [2016](#brb31132-bib-0018){ref-type="ref"}; Koch et al., [2005](#brb31132-bib-0031){ref-type="ref"}; Lefaucheur et al., [2004](#brb31132-bib-0032){ref-type="ref"}; Nardone et al., [2014](#brb31132-bib-0041){ref-type="ref"}; Sedlackova et al., [2009](#brb31132-bib-0049){ref-type="ref"}; Siebner et al., [2000](#brb31132-bib-0051){ref-type="ref"}, three‐six sessions: Filipovic et al., [2009](#brb31132-bib-0017){ref-type="ref"}; Khedr et al., [2006](#brb31132-bib-0028){ref-type="ref"}; Kim et al., [2015](#brb31132-bib-0029){ref-type="ref"}; Maruo et al., [2013](#brb31132-bib-0038){ref-type="ref"}; Yokoe et al., [2018](#brb31132-bib-0057){ref-type="ref"}, eight sessions: Benninger et al., [2011](#brb31132-bib-0001){ref-type="ref"}; Benninger et al., [2012](#brb31132-bib-0002){ref-type="ref"}; Hamada et al., [2008](#brb31132-bib-0021){ref-type="ref"}; Lomarev et al., [2006](#brb31132-bib-0036){ref-type="ref"}; Okabe et al., [2003](#brb31132-bib-0042){ref-type="ref"}; Shirota et al., [2013](#brb31132-bib-0050){ref-type="ref"}; and 10 sessions: Brys et al., [2016](#brb31132-bib-0005){ref-type="ref"}; del Olmo et al., [2007](#brb31132-bib-0013){ref-type="ref"}; Flamez et al., [2016](#brb31132-bib-0018){ref-type="ref"}; Khedr et al., [2003](#brb31132-bib-0027){ref-type="ref"};) (d) dosage of stimulation pulses (from 100 to 4,000 pulses/session); (e) medication status during assessment ("on" or "off" state); (f) the frequency of treatments (1--5 sessions/week); (g) the intensity above motor threshold (80%--120%MT); and (h) type of coil (Figure of 8 or circular coil). Often, rTMS of the M1 resulted in significant improvement of motor function, while rTMS over the SMA, DLPFC, and other sites produced less or no effects. Thus, different parameters between different rTMS studies have made it difficult to interpret and select the optimal rTMS stimulation parameters for PD motor improvement.

Additionally, previous reviews only assessed the rTMS studies that exclusively targeted at primary motor cortex (M1) or at different cortical areas (Elahi & Chen, [2009](#brb31132-bib-0016){ref-type="ref"}; Fregni, Simon, Wu, & Pascual‐Leone, [2005](#brb31132-bib-0019){ref-type="ref"}; Zanjani et al., [2015](#brb31132-bib-0058){ref-type="ref"}). Because the therapeutic effects of rTMS tended to be region‐specific (Kim, Kim, Chun, Yi, & Kwon, [2010](#brb31132-bib-0030){ref-type="ref"}; Levkovitz et al., [2015](#brb31132-bib-0034){ref-type="ref"}; Sasaki, Kakuda, & Abo, [2014](#brb31132-bib-0048){ref-type="ref"}) and dependent on stimulation frequency (Elahi & Chen, [2009](#brb31132-bib-0016){ref-type="ref"}) as well as sessions and pulses, (Chung & Mak, [2016](#brb31132-bib-0008){ref-type="ref"}) the aim of this meta‐analysis was to investigate the rTMS stimulation parameters that produced the optimal therapeutic effects on motor dysfunction of PD.

2. MATERIALS AND METHODS {#brb31132-sec-0006}
========================

2.1. Literature search {#brb31132-sec-0007}
----------------------

Multiple databases, which included PubMed, Medline, Embase, Science Direct, and the Cochrane library, were searched for relevant clinical studies published before 11 April 2018. The search terms were ("Parkinson Disease" or "Parkinson\'s Disease" or "Parkinsonism" or "Parkinsonian") and ("repetitive transcranial magnetic stimulation" or "rTMS" or "repetitive TMS" or "theta burst stimulation" or "TBS").

2.2. Inclusion criteria and exclusion criteria {#brb31132-sec-0008}
----------------------------------------------

The studies were included if they met the following criteria: (a) studies that evaluated the effectiveness of rTMS in adult patients with PD; (b) the design of studies was randomized controlled or crossover design; (c) studies that measured outcomes of motor dysfunction symptoms (motor examination of the Unified Parkinson\'s Disease Rating Scale \[UPDRS‐III\]); (d) the outcomes were reported or could be calculated from the original data of the study; and (e) the studies were published in English. Studies were excluded if the outcome assessments were not or could not be expressed as a mean value ± standard deviation (*SD*).

2.3. Study quality assessment {#brb31132-sec-0009}
-----------------------------

The methodological quality of included studies was assessed by two independent reviewers according to a slight modified checklist from Moher, Schulz, and Altman ([2001](#brb31132-bib-0040){ref-type="ref"}) that contained six aspects: (1) randomization: recorded as "1" if the subjects were randomly allocated in the study and "0" if not; (2) blind procedure: "0" represented a nonblind or nondescribed procedure, and "1" and "2" represented single‐blind and double‐blind procedures, respectively; (3) dropout number was listed and recorded as the number of patients who dropped out from the study; (4) descriptions of baseline demographic and clinical characteristics were recorded as "1" if described, and "0" if not; (5) control design: recorded as "1" if the experiment was designed with healthy controls, "2" with patient controls, and "3" with both controls; and (6) adverse effects were denoted as a number of events.

2.4. Data extraction {#brb31132-sec-0010}
--------------------

The data from each study were extracted by two reviewers independently, and it included study design, sample size, sample characteristics, treatment parameters, medication status during assessment ("on" or "off"), outcome measurements, and the duration of the follow‐up (i.e., assessment made at 1 month or more after the last rTMS session was considered as long‐term outcome; Chung & Mak, [2016](#brb31132-bib-0008){ref-type="ref"}).

If the mean and *SD* of change scores were shown in the articles, they were extracted. If the mean and *SD* of the change scores were not clearly described in article, the change scores were calculated by using the following formula based on the principles of the Cochrane Handbook for Systematic Reviews of Interventions (Higgins, [2011](#brb31132-bib-0022){ref-type="ref"}): $$\text{Mean}_{change} = \text{Mean}_{final} - \text{Mean}_{baseline};$$ $$SD_{change} = \sqrt{SD_{baseline}^{2} + SD_{final}^{2} - {(2 \times \text{Corr} \times SD_{baseline} \times SD_{final})}}$$ If the studies provided the mean values and the standard errors of the means, or reported original materials of each patient, then we calculated the mean values and *SD*s based on the principles of the Cochrane Handbook for Systematic Reviews of Interventions.Higgins, [2011](#brb31132-bib-0022){ref-type="ref"} If the outcome was reported only as a graph, data were extracted by using the software GetData Graph Digitizer 2.25 (<http://getdata-graph-digitizer.com/>).

2.5. Data analysis {#brb31132-sec-0011}
------------------

The data syntheses were conducted by using Reviewer Manager Version 5.3 software from the Cochrane Collaboration (Cochrane Collaboration, Oxford, England). The standardized mean difference (SMD) was calculated to estimate the effect size for clinical scores of the rTMS effect on motor symptoms measured with the UPDRS‐III, with 95% confidence interval (CI). The heterogeneity was tested by using the Cochran\'s Q statistics and *I* ^2^ test (Zintzaras & Ioannidis, [2005](#brb31132-bib-0060){ref-type="ref"}). If the *I* ^2^ value was greater than 50%, the random effect model was used for the analysis. Otherwise a fixed model was used. The Egger\'s test (Egger, Davey Smith, Schneider, & Minder, [1997](#brb31132-bib-0014){ref-type="ref"}) was used to test potential publication bias. Subgroup analysis was also performed based on the rTMS site, rTMS frequency, interaction between rTMS site and rTMS frequency, medication state during assessment ("on" or "off"), treatment sessions, and stimulation pulses. The statistical significance was set at *p* = 0.05.

3. RESULTS {#brb31132-sec-0012}
==========

3.1. Study selection {#brb31132-sec-0013}
--------------------

Of a total of 1,349 relevant studies were found from the above‐mentioned databases, but only 23 studies were included in this meta‐analysis based on the inclusion and exclusion criteria. The flow diagram of the selection process is shown in Figure [1](#brb31132-fig-0001){ref-type="fig"}.

![Flow diagram of literature search](BRB3-8-e01132-g001){#brb31132-fig-0001}

3.2. Quality assessment of the studies {#brb31132-sec-0014}
--------------------------------------

Table [1](#brb31132-tbl-0001){ref-type="table"} shows the quality assessments of the included studies. Randomized allocation of the patients was applied in most studies. Most of these studies were double‐blind or single‐blind. There was insufficient information to categorize the blind procedure in two studies (del Olmo et al., [2007](#brb31132-bib-0013){ref-type="ref"}; Sedlackova et al., [2009](#brb31132-bib-0049){ref-type="ref"}). Nine studies (Benninger et al., [2011](#brb31132-bib-0001){ref-type="ref"}, [2012](#brb31132-bib-0002){ref-type="ref"}; Brys et al., [2016](#brb31132-bib-0005){ref-type="ref"}; Hamada et al., [2008](#brb31132-bib-0021){ref-type="ref"}; Khedr et al., [2003](#brb31132-bib-0027){ref-type="ref"}; Kim et al., [2015](#brb31132-bib-0029){ref-type="ref"}; Lomarev et al., [2006](#brb31132-bib-0036){ref-type="ref"}; Sedlackova et al., [2009](#brb31132-bib-0049){ref-type="ref"}; Shirota et al., [2013](#brb31132-bib-0050){ref-type="ref"}) described the dropout number.

###### 

Quality assessment of the included studies

  Study                                                            Randomization   Blind procedure   Control design   Descriptions of baseline demographic and clinical characteristics   Dropout number   Adverse effects
  ---------------------------------------------------------------- --------------- ----------------- ---------------- ------------------------------------------------------------------- ---------------- -----------------
  Lefaucheur et al. ([2004](#brb31132-bib-0032){ref-type="ref"})   1               2                 2                1                                                                   0                0
  Filipovic et al. ([2009](#brb31132-bib-0017){ref-type="ref"})    1               1                 2                1                                                                   0                0
  Flamez et al. ([2016](#brb31132-bib-0018){ref-type="ref"})       1               2                 2                1                                                                   0                0
  Siebner et al. ([2000](#brb31132-bib-0051){ref-type="ref"})      1               1                 2                1                                                                   0                0
  Khedr et al. ([2003](#brb31132-bib-0027){ref-type="ref"})        1               2                 2                1                                                                   5                0
  Bornke et al. ([2004](#brb31132-bib-0003){ref-type="ref"})       1               2                 2                1                                                                   0                0
  Maruo et al. ([2013](#brb31132-bib-0038){ref-type="ref"})        1               2                 2                1                                                                   0                0
  Khedr et al. ([2006](#brb31132-bib-0028){ref-type="ref"})        1               2                 2                1                                                                   0                U
  Benninger et al. ([2012](#brb31132-bib-0002){ref-type="ref"})    1               2                 2                1                                                                   1                0
  Brys et al. ([2016](#brb31132-bib-0005){ref-type="ref"})         1               2                 2                1                                                                   11               34
  Okabe et al. ([2003](#brb31132-bib-0042){ref-type="ref"})        1               2                 2                1                                                                   0                NR
  Shirota et al. ([2013](#brb31132-bib-0050){ref-type="ref"})      1               2                 2                1                                                                   11               2
  Brusa et al. ([2006](#brb31132-bib-0004){ref-type="ref"})        1               2                 2                1                                                                   0                0
  Koch et al. ([2005](#brb31132-bib-0031){ref-type="ref"})         1               2                 2                1                                                                   0                NR
  Hamada et al. ([2008](#brb31132-bib-0021){ref-type="ref"})       1               2                 2                1                                                                   5                NR
  del Olmo et al. ([2007](#brb31132-bib-0013){ref-type="ref"})     1               0                 2                1                                                                   0                NR
  Sedlackova et al. ([2009](#brb31132-bib-0049){ref-type="ref"})   1               0                 2                1                                                                   1                NR
  Nardone et al. ([2014](#brb31132-bib-0041){ref-type="ref"})      1               1                 3                1                                                                   0                0
  Lomarev et al. ([2006](#brb31132-bib-0036){ref-type="ref"})      1               2                 2                1                                                                   2                1
  Kim et al. ([2015](#brb31132-bib-0029){ref-type="ref"})          1               2                 2                1                                                                   2                1
  Benninger et al. ([2011](#brb31132-bib-0001){ref-type="ref"})    1               2                 2                1                                                                   2                9
  Eggers et al. ([2015](#brb31132-bib-0015){ref-type="ref"})       0               1                 2                1                                                                   0                0
  Yokoe et al. ([2018](#brb31132-bib-0057){ref-type="ref"})        1               2                 2                1                                                                   0                1

U: unclear, insufficient information to count the number of adverse events; NR: not reported.
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3.3. Study characteristics {#brb31132-sec-0015}
--------------------------

The main characteristics of the studies are summarized in Tables [2](#brb31132-tbl-0002){ref-type="table"} and [3](#brb31132-tbl-0003){ref-type="table"}. Table [2](#brb31132-tbl-0002){ref-type="table"} includes the study design, sample size, and the main characteristics of the subjects. Of the 23 studies selected for this meta‐analysis, 10 studies (Benninger et al., [2011](#brb31132-bib-0001){ref-type="ref"}; del Olmo et al., [2007](#brb31132-bib-0013){ref-type="ref"}; Hamada et al., [2008](#brb31132-bib-0021){ref-type="ref"}; Khedr et al., [2003](#brb31132-bib-0027){ref-type="ref"}, [2006](#brb31132-bib-0028){ref-type="ref"}; Lomarev et al., [2006](#brb31132-bib-0036){ref-type="ref"}; Okabe et al., [2003](#brb31132-bib-0042){ref-type="ref"}; Shirota et al., [2013](#brb31132-bib-0050){ref-type="ref"}) were parallel controlled and 13 studies (Bornke et al., [2004](#brb31132-bib-0003){ref-type="ref"}; Brusa et al., [2006](#brb31132-bib-0004){ref-type="ref"}; Eggers et al., [2015](#brb31132-bib-0015){ref-type="ref"}; Filipovic et al., [2009](#brb31132-bib-0017){ref-type="ref"}; Flamez et al., [2016](#brb31132-bib-0018){ref-type="ref"}; Kim et al., [2015](#brb31132-bib-0029){ref-type="ref"}; Koch et al., [2005](#brb31132-bib-0031){ref-type="ref"}; Lefaucheur et al., [2004](#brb31132-bib-0032){ref-type="ref"}; Maruo et al., [2013](#brb31132-bib-0038){ref-type="ref"}; Nardone et al., [2014](#brb31132-bib-0041){ref-type="ref"}; Sedlackova et al., [2009](#brb31132-bib-0049){ref-type="ref"}; Siebner et al., [2000](#brb31132-bib-0051){ref-type="ref"}; Yokoe et al., [2018](#brb31132-bib-0057){ref-type="ref"}) were crossover controlled. Table [3](#brb31132-tbl-0003){ref-type="table"} shows the rTMS stimulation parameters including the site, frequency, intensity, sessions.

###### 

Characteristics of the included trails

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                                                            Design      Sample size       Age(y)            Sex (M/F)       Disease duration (y)   H&Y stage
  ---------------------------------------------------------------- ----------- ----------------- ----------------- --------------- ---------------------- -------------------
  Benninger et al. ([2012](#brb31132-bib-0002){ref-type="ref"})    Parallel    Ne:13\            Ne:64.5 ± 9.1\    Ne:11/2\        Ne:8.6 ± 4.1\          2--4
                                                                               Nc:13             Nc:63.7 ± 8.3     Nc:9/4          Nc:9.3 ± 6.8           

  Khedr et al. ([2003](#brb31132-bib-0027){ref-type="ref"})        Parallel    Ne:19\            Ne:57.8 ± 9.2\    Ne:14/5\        Ne:3.05 ± 2.1\         2--3
                                                                               Nc:17             Nc:57.5 ± 8.4     Nc:10/7         Nc:3.6 ± 2.4           

  Kim et al. ([2015](#brb31132-bib-0029){ref-type="ref"})          Crossover   17                64.5 ± 8.4        12/5            7.8 ± 4.9              3.0 ± 0.5

  Khedr et al. ([2006](#brb31132-bib-0028){ref-type="ref"})        Parallel    Ne:10\            Ne:60.2 ± 9.48\   NR              Ne:4.6 ± 2.26\         Ne:3.5 ± 0.7\
                                                                               Nc:10             Nc:60.6 ± 10.3                    Nc:4.6 ± 1.97          Nc:3.8 ± 0.9

  Bornke et al. ([2004](#brb31132-bib-0003){ref-type="ref"})       Crossover   12                55.92 ± 13.09     6/6             NR                     2.25 ± 0.8

  Filipovic et al. ([2009](#brb31132-bib-0017){ref-type="ref"})    Crossover   10                64.5 ± 9.6        5/5             15.6 ± 5.7             NR

  Flamez et al. ([2016](#brb31132-bib-0018){ref-type="ref"})       Crossover   9                 70 ± 5.9          4/5             13.8 ± 5.6             3 ± 1

  Crossover                                                        6           68.8 ± 10.3       4/2               14.0 ± 5.0      3 ± 1                  

  Lefaucheur et al. ([2004](#brb31132-bib-0032){ref-type="ref"})   Crossover   12                64 ± 6.9          7/5             11 ± 3.5               3.4 ± 0.2

  Maruo et al. ([2013](#brb31132-bib-0038){ref-type="ref"})        Crossover   21                63.0 ± 11.3       11/10           12.0 ± 6.3             3.1 ± 0.5

  Siebner et al. ([2000](#brb31132-bib-0051){ref-type="ref"})      Crossover   10                57 ± 11           7/3             5.5 ± 3.4              1--2.5

  Hamada et al. ([2008](#brb31132-bib-0021){ref-type="ref"})       Parallel    Ne:55\            Ne:65.3 ± 8.9\    Ne:29/24\       Ne:8.1 ± 4.2\          2--4
                                                                               Nc:43             Nc:67.4 ± 8.5     Nc:25/15        Nc:7.8 ± 6.7           

  Shirota et al. ([2013](#brb31132-bib-0050){ref-type="ref"})      Parallel    34/34/34          L:68.8 ± 67.6\    NR              L:8.5 ± 7.3\           2--4
                                                                                                 H:67.9 ± 68.4\                    H:7.8 ± 6.6\           
                                                                                                 Nc:65.7 ± 68.5                    Nc:7.6 ± 4.4           

  Brusa et al. ([2006](#brb31132-bib-0004){ref-type="ref"})        Crossover   10                61 ± 8.04         6/4             16.4 ± 5.4             NR

  Koch et al. ([2005](#brb31132-bib-0031){ref-type="ref"})         Crossover   8                 60.75 ± 9.84      4/4             16.5 ± 5.93            NR

  Nardone et al. ([2014](#brb31132-bib-0041){ref-type="ref"})      Crossover   4                 65.75 ± 3.5       3/1             10.25 ± 4.57           NR

  del Olmo et al. ([2007](#brb31132-bib-0013){ref-type="ref"})     Parallel    Ne:8\             61.7 ± 5.22       6/7             8 ± 5                  1--3
                                                                               Nc:5                                                                       

  Sedlackova et al. ([2009](#brb31132-bib-0049){ref-type="ref"})   Crossover   10                63.7 ± 6.7        9/1             7.8 ± 6.5              NR

  Crossover                                                        10          63.7 ± 6.7        9/1               7.8 ± 6.5       NR                     

  Brys et al. ([2016](#brb31132-bib-0005){ref-type="ref"})         Parallel    Ne:14\            Ne:59.6 ± 12.6\   Ne:9/5\         Ne:8.4 ± 5.2\          2--4
                                                                               Nc:15             Nc:64.0 ± 7.4     Nc:11/4         Nc:4.5 ± 2.2           

  Parallel                                                         Ne:12\      Ne:64.6 ± 12.3\   Ne:6/6\           Ne:7.7 ± 4.2\   2--4                   
                                                                   Nc:15       Nc:64.0 ± 7.4     Nc:11/4           Nc:4.5 ± 2.2                           

  Parallel                                                         Ne:20\      Ne:64.9 ± 8.0\    Ne:11/9\          Ne:7.3 ± 5.6\   2--4                   
                                                                   Nc:15       Nc:64.0 ± 7.4     Nc:11/4           Nc:4.5 ± 2.2                           

  Lomarev et al. ([2006](#brb31132-bib-0036){ref-type="ref"})      Parallel    Ne:9\             Ne:63 ± 10\       Ne:7/2\         Ne:13.8 ± 6.8\         2--4
                                                                               Nc:9              Nc:66 ± 10        Nc:8/1          Nc:10.8 ± 3.1          

  Okabe et al. ([2003](#brb31132-bib-0042){ref-type="ref"})        Parallel    Ne:28\            67.2 ± 8.2        NR              Ne:8.8 ± 5.1\          Ne:3.11 ± 0.92\
                                                                               Nc:28                                               Nc:8.0 ± 5.4           Nc:2.92 ± 0.83

  Parallel                                                         Ne:29\      67.2 ± 8.2        NR                Ne:8.8 ± 6.4\   Ne:2.95 ± 0.83\        
                                                                   Nc:28                                           Nc:8.0 ± 5.4    Nc:2.92 ± 0.83         

  Benninger et al. ([2011](#brb31132-bib-0001){ref-type="ref"})    Parallel    Ne:13\            Ne:62.1 ± 6.9\    Ne:7/6\         Ne:10.8 ± 7.1\         Ne:2.6 ± 0.2(on)\
                                                                               Nc:13             Nc:65.6 ± 9.0     Nc:11/2         Nc:6.5 ± 3.4           3.0 ± 0.4(off)\
                                                                                                                                                          Nc:2.5 ± 0.1(on)\
                                                                                                                                                          2.9 ± 0.2(off)

  Eggers et al. ([2015](#brb31132-bib-0015){ref-type="ref"})       Crossover   13                Off:64.7 ± 5.0    Off:4/9         Off:5.8 ± 4.3          Off:1.8 ± 0.8

  Crossover                                                        13          On:60.8 ± 7.8     On:6/7            On:7.1 ± 4.7    On:1.7 ± 0.8           

  Yokoe et al. ([2018](#brb31132-bib-0057){ref-type="ref"})        Crossover   19                69.1 ± 8.4        7/12            9.5 ± 3.2              3.5 ± 0.6

  Crossover                                                        19          69.1 ± 8.4        7/12              9.5 ± 3.2       3.5 ± 0.6              

  Crossover                                                        19          69.1 ± 8.4        7/12              9.5 ± 3.2       3.5 ± 0.6              
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------

H&Y, Hoehn and Yahr Stage; Ne, number of experimental group; Nc, number of control group; NR, not reported.
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###### 

Treatment parameters, clinical assessment, and follow‐up

  Study                                                            Stimulation parameters   Sham rTMS   Status    Session duration   Follow‐up                                                                     
  ---------------------------------------------------------------- ------------------------ ----------- --------- ------------------ --------------------- --------------------------- ------------ -------------- ----------------------
  Benninger et al. ([2012](#brb31132-bib-0002){ref-type="ref"})    50 Hz                    80%AMT      C         600                M1                    Inactive and active coils   On and Off   8/2 weeks      1 month
  Khedr et al. ([2003](#brb31132-bib-0027){ref-type="ref"})        5 Hz                     120%RMT     F8        2,000              M1                    Tilted coil                 Off          10/10 day      1 month
  Kim et al. ([2015](#brb31132-bib-0029){ref-type="ref"})          10 Hz                    90%RMT      Dc        1,000              M1                    Tilted coil                 On           5/5 days       2 weeks
  Khedr et al. ([2006](#brb31132-bib-0028){ref-type="ref"})        10 Hz                    100%RMT     F8        3,000              M1                    Occipital stimulation       Off          6/6 days       1 month
  Bornke et al. ([2004](#brb31132-bib-0003){ref-type="ref"})       10 Hz                    90%RMT      F8        1,000              M1                    Tilted coil                 Off          1 days         No
  Filipovic et al. ([2009](#brb31132-bib-0017){ref-type="ref"})    1 Hz                     \~90%RMT    F8        1,800              M1                    Sham coil                   On and Off   4/4 days       No
  Flamez et al. ([2016](#brb31132-bib-0018){ref-type="ref"})       1 Hz                     90%RMT      F8        2,000              M1                    Tilted coil                 On           1 day          No
  1 Hz                                                             90%RMT                   F8          2,000     M1                 Tilted coil           On                          10/5 days    2 weeks        
  Lefaucheur et al. ([2004](#brb31132-bib-0032){ref-type="ref"})   L:0.5 Hz                 80%RMT      F8        L:600              M1                    Sham coil                   Off          1 day          No
  H:10 Hz                                                          80%RMT                   F8          H:2,000   M1                 Sham coil             Off                         1d           No             
  Maruo et al. ([2013](#brb31132-bib-0038){ref-type="ref"})        10 Hz                    100%RMT     F8        1,000              M1                    Realistic Sham              Off          3/3 days       No
  Siebner et al. ([2000](#brb31132-bib-0051){ref-type="ref"})      5 Hz                     90%RMT      F8        2,250              M1                    Tilted coil                 Off          1 day          No
  Hamada et al. ([2008](#brb31132-bib-0021){ref-type="ref"});      5 Hz                     110%AMT     F8        1,000              SMA                   Realistic Sham              On           8/8 weeks      1 month
  Shirota et al. ([2013](#brb31132-bib-0050){ref-type="ref"})      L:1 Hz                   110%AMT     F8        L:1,000            SMA                   Realistic Sham              On           8/8 weeks      1, 12 weeks
  H:10 Hz                                                          110%AMT                  F8          H:1000    SMA                Realistic Sham        On                          8/8 weeks    1, 12 weeks    
  Brusa et al. ([2006](#brb31132-bib-0004){ref-type="ref"})        1 Hz                     90%RMT      F8        900                SMA                   Tilted coil                 On           1 day          No
  Koch et al. ([2005](#brb31132-bib-0031){ref-type="ref"})         L:1 Hz                   90%RMT      F8        900                SMA                   Tilted coil                 On           1 day          No
  H:5 Hz                                                           110%RMT                  F8          900       SMA                Tilted coil           On                          1 day        No             
  Nardone et al. ([2014](#brb31132-bib-0041){ref-type="ref"})      1 Hz                     Below AMT   F8        1800               DLPFC                 Sham coil                   On           1 day          No
  del Olmo et al. ([2007](#brb31132-bib-0013){ref-type="ref"})     10 Hz                    90%AMT      F8        450                DLPFC                 Tilted coil                 On           10/10 days     No
  Sedlackova et al. ([2009](#brb31132-bib-0049){ref-type="ref"})   10 Hz                    100%RMT     F8        1350               DLPFC                 Occipital Stimution         Off          1 day          No
  10 Hz                                                            100%RMT                  F8          1,350     PMD                Occipital Stimution   Off                         1 day        No             
  Brys et al. ([2016](#brb31132-bib-0005){ref-type="ref"})         10 Hz                    NR          F8        2,000              M1                    Sham coil                   Off          10/2 weeks     1 week, 1,3,6 months
  10 Hz                                                            NR                       F8          2,000     DLPFC              Sham coil             Off                         10/2 weeks   1,3,6 months   
  10 Hz                                                            NR                       F8          3,000     M1 + DLPFC         Sham coil             Off                         10/2 weeks   1,3,6 months   
  Lomarev et al. ([2006](#brb31132-bib-0036){ref-type="ref"})      25 Hz                    100%RMT     F8        1,200              M1 + DLPFC            Coil inactive surface       On and off   8/4 weeks      1 months
  Okabe et al. ([2003](#brb31132-bib-0042){ref-type="ref"})        0.2 Hz                   110%AMT     C         100                M1                    Sham coil                   On           8/8 weeks      1,2 months
  0.2 Hz                                                           110%AMT                  C           100       Occipital          Sham coil             On                          8/8 weeks    1,2 months     
  Benninger et al. ([2011](#brb31132-bib-0001){ref-type="ref"})    50 Hz                    80%AMT      C         2,400              M1 + DLPFC            Sham coil                   On and off   8/2 weeks      1 months
  Eggers et al. ([2015](#brb31132-bib-0015){ref-type="ref"})       50 Hz                    90%AMT      F8        600                SMA                   Title coil                  Off          1 day          No
  50 Hz                                                            90%AMT                   F8          600       SMA                Title coil            On                          1 day        No             
  Yokoe et al. ([2018](#brb31132-bib-0057){ref-type="ref"})        10 Hz                    100%RMT     C         1,000              M1                    Sham coil                   On           3 days         No
  10 Hz                                                            100%RMT                  C           1,000     SMA                Sham coil             On                          3 days       No             
  10 Hz                                                            100%RMT                  C           1,000     DLPFC              Sham coil             On                          3 days       No             

AMT: active motor threshold; RMT: resting motor threshold; C: circular; F8: figure of 8; Dc: double coil; M1: primary motor cortex; SMA: supplementary motor area; DLPFC: dorsolateral prefrontal cortex; PMD: dorsal premotor cortex; NR: not reported; H: high‐frequency group; L: low‐frequency group.
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3.4. Adverse effects {#brb31132-sec-0016}
--------------------

Seventeen studies (Benninger et al., [2011](#brb31132-bib-0001){ref-type="ref"}, [2012](#brb31132-bib-0002){ref-type="ref"}; Bornke et al., [2004](#brb31132-bib-0003){ref-type="ref"}; Brusa et al., [2006](#brb31132-bib-0004){ref-type="ref"}; Brys et al., [2016](#brb31132-bib-0005){ref-type="ref"}; Filipovic et al., [2009](#brb31132-bib-0017){ref-type="ref"}; Flamez et al., [2016](#brb31132-bib-0018){ref-type="ref"}; Khedr et al., [2003](#brb31132-bib-0027){ref-type="ref"}, [2006](#brb31132-bib-0028){ref-type="ref"}; Kim et al., [2015](#brb31132-bib-0029){ref-type="ref"}; Lefaucheur et al., [2004](#brb31132-bib-0032){ref-type="ref"}; Lomarev et al., [2006](#brb31132-bib-0036){ref-type="ref"}; Maruo et al., [2013](#brb31132-bib-0038){ref-type="ref"}; Nardone et al., [2014](#brb31132-bib-0041){ref-type="ref"}; Shirota et al., [2013](#brb31132-bib-0050){ref-type="ref"}; Siebner et al., [2000](#brb31132-bib-0051){ref-type="ref"}; Yokoe et al., [2018](#brb31132-bib-0057){ref-type="ref"}) evaluated the incidence of adverse effects. Of these, 11 studies (Benninger et al., [2012](#brb31132-bib-0002){ref-type="ref"}; Bornke et al., [2004](#brb31132-bib-0003){ref-type="ref"}; Brusa et al., [2006](#brb31132-bib-0004){ref-type="ref"}; Eggers et al., [2015](#brb31132-bib-0015){ref-type="ref"}; Filipovic et al., [2009](#brb31132-bib-0017){ref-type="ref"}; Flamez et al., [2016](#brb31132-bib-0018){ref-type="ref"}; Khedr et al., [2003](#brb31132-bib-0027){ref-type="ref"}; Lefaucheur et al., [2004](#brb31132-bib-0032){ref-type="ref"}; Maruo et al., [2013](#brb31132-bib-0038){ref-type="ref"}; Nardone et al., [2014](#brb31132-bib-0041){ref-type="ref"}; Siebner et al., [2000](#brb31132-bib-0051){ref-type="ref"}) showed no adverse effects of rTMS. Khedr et al. ([2006](#brb31132-bib-0028){ref-type="ref"}) reported an occasional mild, transient headache in some patients. Brys et al. ([2016](#brb31132-bib-0005){ref-type="ref"}) reported adverse effects in 25 active rTMS and nine sham rTMS‐treated PD patients, respectively. The most common adverse effects were mild and transient headache and neck pain. Shirota et al. ([2013](#brb31132-bib-0050){ref-type="ref"}) reported that two patients experienced tinnitus and headache. Kim et al. ([2015](#brb31132-bib-0029){ref-type="ref"}) reported that one patient had a mild headache which disappeared soon after the stop of rTMS. Lomarev et al. ([2006](#brb31132-bib-0036){ref-type="ref"}) reported that one patient could not tolerate the pain under the coil in the rTMS group. Benninger et al. ([2011](#brb31132-bib-0001){ref-type="ref"}) reported that nine patients had occasional local pain or discomfort during iTBS stimulation, predominantly of DLPFC, and one patient had an isolated, nonpulsatile, left‐sided tinnitus for a few minutes. Yokoe et al. ([2018](#brb31132-bib-0057){ref-type="ref"}) reported that one patient had a mild headache during the DLPFC stimulation that spontaneously resolved.

3.5. Synthesis of results {#brb31132-sec-0017}
-------------------------

A total of 33 trials of the selected 23 articles compared the effect of rTMS on motor signs. The results of pooled data showed a significant improvement after rTMS therapy (SMD, 0.37; 95% CI, 0.24--0.50; *p* \< 0.00001; *I* ^2^ = 29%; Figure [2](#brb31132-fig-0002){ref-type="fig"}). The Egger\'s test (*p* = 0.41) showed no significant publication bias.

![Forest plot from the meta‐analysis of rTMS on UPDRS‐III scores at short‐term showing estimates of mean effect size with 95% confidence interval (95% CI). Studies denoted as "on" or "off" distinguish those with assessment done both in "on" and "off" medication state](BRB3-8-e01132-g002){#brb31132-fig-0002}

The result of the subgroup analysis for medication state ("on" or "off") during assessment was as also calculated (Figure [3](#brb31132-fig-0003){ref-type="fig"}). No significant difference of the mean therapeutic effect size of rTMS for UPDRS‐III was observed between "on" state (SMD, 0.32; 95% CI, 0.17--0.48; *p* \< 0.0001; *I* ^2^ = 37%) and "off" state (SMD, 0.34; 95% CI, 0.15--0.54; *p* = 0.0005; *I* ^2^ = 6%).

![Forest plot of rTMS on UPDRS‐III scores measured during "on" and "off" medication state showing estimates of mean effect size with 95% confidence interval (95% CI). Studies denoted as "on" or "off" distinguish those with assessment done both in "on" and "off" medication state](BRB3-8-e01132-g003){#brb31132-fig-0003}

The stimulation frequency subgroup analysis is presented as Figure [4](#brb31132-fig-0004){ref-type="fig"}. The frequency subgroup analysis revealed a significant improvement in the UPDRS‐III only after HF‐rTMS (SMD, 0.48; 95% CI, 0.32--0.64; *p* \< 0.00001; *I* ^2^ = 45%) but not after LF‐rTMS (SMD, 0.19; 95% CI, −0.04--0.42; *p* = 0.11; *I* ^2^ = 0%).

![Forest plots of rTMS on UPDRS‐III scores for studies comparing high‐frequency and low‐frequency rTMS protocol showing estimates of mean effect size with 95% confidence interval (95% CI). Studies denoted as "on" or "off" distinguish those with assessment done both in "on" and "off" medication state](BRB3-8-e01132-g004){#brb31132-fig-0004}

The subgroup analysis of rTMS sites showed the following order of mean effect sizes of rTMS on UPDRS‐III: 0.52 (95% CI, 0.32--0.72; *p* \< 0.00001; *I* ^2^ = 42%) for M1; 0.30 (95% CI, 0.08--0.52; *p* = 0.008; *I* ^2^ = 35%) for SMA; 0.29 (95% CI, −0.11--0.68; *p* = 0.15; *I* ^2^ = 25%) for DLPFC; 0.27 (95% CI, −0.18--0.73; *p* = 0.23; *I* ^2^ = 0%) for other regions, and 0.10 (95% CI, −0.35--0.55; *p* = 0.66; *I* ^2^ = 0%) for complex region, respectively (Figure [5](#brb31132-fig-0005){ref-type="fig"}). The M1 and SMA sites revealed the significant improvement after rTMS therapy.

![Forest plots of rTMS on UPDRS‐III scores for studies comparing the stimulation site of primary motor cortex (M1), supplementary motor area (SMA), dorsal lateral prefrontal cortex (DLPFC), the other regions and complex region (M1 +  DLPFC) showing estimates of mean effect size with 95% confidence interval (95% CI). Studies denoted as "on" or "off" distinguish those with assessment done both in "on" and "off" medication state](BRB3-8-e01132-g005){#brb31132-fig-0005}

As the HF‐rTMS was more effective than LF‐rTMS for improving Parkinson\'s motor symptoms (Figure [4](#brb31132-fig-0004){ref-type="fig"}), we further re‐analyzed the site effect of HF‐rTMS therapy on UPDRS‐III, with the following results: 0.66 (95% CI, 0.29--1.02; *p* = 0.0005; *I* ^2^ = 56%) for M1; 0.42 (95% CI, −0.09--0.93; *p* = 0.1; *I* ^2^ = 65%) for SMA; 0.37 (95% CI, −0.04--0.78; *p* = 0.07; *I* ^2^ = 0%) for DLPFC; 0.14 (95% CI, −0.76--1.04; *p* = 0.76) for other region, and 0.13 (95% CI, −0.43--0.69; *p* = 0.65; *I* ^2^ = 0%) for complex region (M1 + DLPFC), respectively (Figure [6](#brb31132-fig-0006){ref-type="fig"}).

![The interaction between high‐frequency rTMS and stimulation site of rTMS on UPDRS‐III scores showing estimates of mean effect size with 95% confidence interval (95% CI). Studies denoted as "on" or "off" distinguish those with assessment done both in "on" and "off" medication state](BRB3-8-e01132-g006){#brb31132-fig-0006}

The bilateral/unilateral stimulation would also influence the rTMS effect. The mean effect sizes of bilateral and unilateral stimulation of HF‐rTMS over M1 were the following results: 0.96 (95% CI, 0.33--1.60; *p* = 0.003; *I* ^2^ = 69%) and 0.35 (95% CI, 0.02--0.68; *p* = 0.04; *I* ^2^ = 0%), respectively (Figure [7](#brb31132-fig-0007){ref-type="fig"}).

![Forest plots of HF‐rTMS over M1 on UPDRS‐III scores for studies comparing the bilateral vs unilateral stimulation of rTMS protocol showing estimates of mean effect size with 95% confidence interval (95% CI). Studies denoted as "on" or "off" distinguish those with assessment done both in "on" and "off" medication state](BRB3-8-e01132-g007){#brb31132-fig-0007}

Ten studies of HF‐rTMS over M1 were further divided into subgroups according to the single‐session and multi‐session of rTMS treatment: single‐session (SMD, 0.36; 95% CI, −0.12--0.85; *p* = 0.14; *I* ^2^ = 0%) and multi‐session (SMD, 0.77; 95% CI, 0.28--1.25; *p* = 0.002; *I* ^2^ = 67%) (Figure [8](#brb31132-fig-0008){ref-type="fig"}). Multi‐session showed a significantly larger effect size than single‐session rTMS.

![Forest plots of HF‐rTMS over M1 on UPDRS‐III scores for studies comparing the single‐ and multi‐session of rTMS protocol showing estimates of mean effect size with 95% confidence interval (95% CI). Studies denoted as "on" or "off" distinguish those with assessment done both in "on" and "off" medication state](BRB3-8-e01132-g008){#brb31132-fig-0008}

The mean effect sizes of the multi‐session total numbers of HF‐rTMS pulses (3,000--5,000 pulses and 18,000--20,000 pulses) delivered over M1 were the following results: 0.63 (95% CI, −0.04--1.3; *p* = 0.06; *I* ^2^ = 73%) and 0.97 (95% CI, 0.22--1.72; *p* = 0.01; *I* ^2^ = 62%) (Figure [9](#brb31132-fig-0009){ref-type="fig"}).

![Forest plots of HF‐rTMS over M1 on UPDRS‐III scores for studies comparing the different total pulses of rTMS protocol showing estimates of mean effect size with 95% confidence interval (95% CI). Studies denoted as "on" or "off" distinguish those with assessment done both in "on" and "off" medication state](BRB3-8-e01132-g009){#brb31132-fig-0009}

3.6. Long‐term follow‐up of motor outcome {#brb31132-sec-0018}
-----------------------------------------

Twelve trials reported the long‐term effect size of rTMS for UPDRS‐III. The pooled effect size showed significant benefit effect of rTMS (SMD, 0.38; 95% CI, 0.11--0.65; *p* = 0.007) with a moderate level of heterogeneity (*I* ^2^ = 55%) and a lack of any publication bias (Egger\'s test, *p* = 0.57) (Figure [10](#brb31132-fig-0010){ref-type="fig"}).

![Forest plot from the meta‐analysis of rTMS on UPDRS‐III scores at long‐term estimates of mean effect size with 95% confidence interval (95% CI). Studies denoted as "on" or "off" distinguish those with assessment done both in "on" and "off" medication state](BRB3-8-e01132-g010){#brb31132-fig-0010}

4. DISCUSSION {#brb31132-sec-0019}
=============

This meta‐analysis indicated more accurate evidence to support the efficacy of rTMS on motor recovery of PD patients. These results suggest that rTMS might be helpful in improving the motor deficits of PD patients. In particular, HF‐rTMS appears more significant effect than LF‐rTMS and significant difference also is found; stimulation over M1 shows better efficacy than other stimulation sites; bilateral stimulation is more effective than unilateral stimulation; multi‐session and higher dosage of pulses (total 18,000--20,000 pulses) are associated with better motor outcome. Additionally, the effect of rTMS appears to be long‐lasting and unaffected by the patient\'s medication state.

Subgroup analysis result for the effects of HF‐rTMS versus LF‐rTMS was consistent with the previous report of Elahi and Chen ([2009](#brb31132-bib-0016){ref-type="ref"}). Who found a significant effect size of UPDRS‐III for HF‐rTMS studies but not significant for LF‐rTMS studies. Distinct results, however, were observed in some other meta‐analysis studies in which no significant difference between HF‐rTMS and LF‐rTMS was found (Chou et al., [2015](#brb31132-bib-0007){ref-type="ref"}); an opposite result was discovered (Wagle Shukla et al., [2016](#brb31132-bib-0055){ref-type="ref"}) or no significant result was observed both in HF‐rTMS and LF‐rTMS (Chung & Mak, [2016](#brb31132-bib-0008){ref-type="ref"}). The reasons for these distinctions may be due to the differences in the included trials, (Zhu et al., [2015](#brb31132-bib-0059){ref-type="ref"}) data extraction, (Chou et al., [2015](#brb31132-bib-0007){ref-type="ref"}) and statistical methods (Wagle Shukla et al., [2016](#brb31132-bib-0055){ref-type="ref"}). Compared with these previous published meta‐analyses, this study enrolled more trials and calculated more detailed subgroup analyses. Therefore, except for the consistent results with previous studies, more new results were discovered including bilateral stimulation, HF‐rTMS over M1 in this meta‐analysis.

The subgroup analysis for rTMS site in this current analysis showed that rTMS targeting the M1 and SMA were significantly effective for PD patients with motor signs. In addition, rTMS over the M1 is more effective than stimulation over the SMA. A previous study gained the similar result (Chung & Mak, [2016](#brb31132-bib-0008){ref-type="ref"}). Moreover, Zanjani et al. ([2015](#brb31132-bib-0058){ref-type="ref"}) only included the studies that rTMS targeted the M1 which also showed positive effect. However, the combination of rTMS frequency and rTMS site in this current analysis revealed that only HF‐rTMS at M1 showed significant effect size, HF‐rTMS targeting the SMA, DLPFC, and M1 + DLPFC were insignificant. The neuroimaging studies which use simple motor tasks to investigate bradykinesia‐related neural activity in PD patients showed significantly decreased activation in the caudate nucleus among other regions (Rolls, Thorpe, & Maddison, [1983](#brb31132-bib-0047){ref-type="ref"}). It is known that PD results from the loss of dopaminergic innervation to the dorsal striatum, a main components of the basal ganglia that is highly innervated by dopamine neurons that originate from the substantia nigra pars compacta (SNc). Basal ganglia are also strongly interconnected with the cerebral cortex (including the M1, thalamus, brainstem, and several other brain areas).

A hypo active caudate nucleus may underlie the motor deficits in PD patients through interfering with the normal functioning of the striato‐frontal motor loop (Rolls et al., [1983](#brb31132-bib-0047){ref-type="ref"}). Gonzalez‐Garcia et al. ([2011](#brb31132-bib-0020){ref-type="ref"}) found that HF‐rTMS over the M1 significantly improved motor behavior and increased motor‐related activity in the caudate nucleus. It has been suggested that striatal dopamine depletion results in an over‐inhibition of neuronal activity in the motor thalamus and consequently the hypo activity in cortical motor and association areas (Conditions TNCCfC, [2006](#brb31132-bib-0011){ref-type="ref"}). Other study showed that rTMS applied to the M1 increased dopamine release in the nigrostriatal system (Strafella, Paus, Fraraccio, & Dagher, [2003](#brb31132-bib-0053){ref-type="ref"}). Therefore, HF‐rTMS over the M1 may improve motor function through increased motor‐related activity in the caudate nucleus and dopamine release in the nigrostriatal system.

Previous studies indicate that HF‐rTMS could facilitate SMA activation and provide symptomatic relief in PD patients (Jenkins et al., [1992](#brb31132-bib-0026){ref-type="ref"}; Playford et al., [1992](#brb31132-bib-0045){ref-type="ref"}; Rascol et al., [1997](#brb31132-bib-0046){ref-type="ref"}). Hamada et al. ([2008](#brb31132-bib-0021){ref-type="ref"}) and Yokoe et al. ([2018](#brb31132-bib-0057){ref-type="ref"}) reported prominent motor improvement after HF‐rTMS over the SMA. However, that result was not reproduced by a multicenter trial with the same stimulation site and session numbers (Shirota et al., [2013](#brb31132-bib-0050){ref-type="ref"}). Two other studies showed no effect of one session HF‐rTMS (Koch et al., [2005](#brb31132-bib-0031){ref-type="ref"}) or LF‐rTMS (Brusa et al., [2006](#brb31132-bib-0004){ref-type="ref"}) over the SMA on UPDRS‐III. More studies are needed to clarify the effectiveness of rTMS targeting the SMA.

Despite of the cortico‐cortical connections with the parietal and premotor cortices' involvement in visuo‐motor control of action and the crucial role of DLPFC in the cognitive control of motor behavior (Kim et al., [2015](#brb31132-bib-0029){ref-type="ref"}), our meta‐analysis did not show significant motor benefit after rTMS over the DLPFC in terms of the UPDRS‐III scores. Other studies showed no effect of rTMS over DLPFC on clinical Parkinsonian symptoms, motor performance of ballistic wrist movements,or synergistic effects of motor signs improvement of rTMS over DLPFC+M1 (Conditions TNCCfC, [2006](#brb31132-bib-0011){ref-type="ref"}). However, it has been suggested that changes in different motor tasks specifically related to DLPFC function (motor planning and response selection) could be more sensitive to measure motor improvement induced by rTMS over this area (Kim et al., [2015](#brb31132-bib-0029){ref-type="ref"}).

The subgroup analysis for bilateral versus unilateral stimulation of HF‐rTMS over the M1 showed that the bilateral stimulation over the M1 was more effective than unilateral stimulation over the M1 for PD with motor signs. The greater motor improvement in bilateral stimulation suggests that bilateral M1 stimulation may have a superimposed effect.

The efficacy of HF‐rTMS appears to be session number‐dependent. Our results showed that, in the short‐term, multi‐session of HF‐rTMS over the M1 is more effective than a single‐session in improving the motor deficits. Khedr et al. ([2003](#brb31132-bib-0027){ref-type="ref"}) showed gradual development of long‐lasting effects over repeated sessions of rTMS. Repeated and long‐term TMS of the brain may cause lasting effects on excitability probably due to cumulative effects of multi‐session on synaptic connections analogous to long‐term potentiation (Platz & Rothwell, [2010](#brb31132-bib-0044){ref-type="ref"}). More sessions of rTMS are often associated with increased dosage or numbers of rTMS stimulation pulses which is another factor underlying the efficacy of rTMS. It would be interesting to know if there are any differences in efficacy between a single‐session and multiple sessions of rTMS that delivered equal doses of pulses. That could reveal the optimal combination of session numbers and pulse dosage for best therapeutic outcomes. In this analysis, we had few single‐session trials that had different doses of pulses to allow such analysis. Our subgroup analysis showed the effect size was statistically significant for trials of multiple sessions with higher number of total stimulation pulses (range from 18,000 to 20,000 pulses). This is in line with an earlier review that indicates a larger effect size of rTMS on UPDRS‐III scores is associated with a greater number of stimulation pulses (Chung & Mak, [2016](#brb31132-bib-0008){ref-type="ref"}). One study of rTMS on major depression showed that 1,200--1,500 pulses/day for 10 or 20 sessions (a total of dose between 12,000 and 30,000 pulses) had the best anxiolytic effects (Teng et al., [2017](#brb31132-bib-0054){ref-type="ref"}). Based on these results and others, one can anticipate that an optimal daily pulses dosage of HF‐rTMS over the M1 for an extended period of time could deliver an optimal efficacy for PD patients.

Previous studies evaluated the long‐term effect of rTMS on motor function in PD patients (Chou et al., [2015](#brb31132-bib-0007){ref-type="ref"}; Chung & Mak, [2016](#brb31132-bib-0008){ref-type="ref"}; Wagle Shukla et al., [2016](#brb31132-bib-0055){ref-type="ref"}; Zanjani et al., [2015](#brb31132-bib-0058){ref-type="ref"}). Chou et al. ([2015](#brb31132-bib-0007){ref-type="ref"}) reported the significant long‐term improvement in motor function in PD patients, and the follow‐up was conducted at 1 week or more after the last rTMS session. However, the other two studies estimated the long‐term effects of rTMS when the follow‐up was conducted at 1 month or more after the last rTMS session (Chung & Mak, [2016](#brb31132-bib-0008){ref-type="ref"}; Zanjani et al., [2015](#brb31132-bib-0058){ref-type="ref"}). Zanjani et al. ([2015](#brb31132-bib-0058){ref-type="ref"}) reported nonsignificant effect size while Chung and Mak ([2016](#brb31132-bib-0008){ref-type="ref"}) reported significant long‐term effects. Wagle Shukla et al. ([2016](#brb31132-bib-0055){ref-type="ref"}) reported nonsignificant long‐term effects, and in this study, there was no clear definition of how long after the last rTMS session was considered as long‐term follow‐up. They only reported the average follow‐up period, it was 6 weeks. Our present meta‐analysis showed the significant long‐term improvement in motor function in PD patients after rTMS treatment. In this meta‐analysis, the long‐term effect refers to the effect at 1 month or more after the last multiple rTMS sessions of treatment, while single‐session does not involve long‐term effects. The postsynaptic changes and the expansion of the short‐term range of plasticity may underlie the cumulative long‐lasting effect of rTMS in patients with PD (Lomarev et al., [2006](#brb31132-bib-0036){ref-type="ref"}). Repeated episodes of long‐term potentiation could also result in increased synapses activity and strength to facilitate neural remodeling (Leuner & Shors, [2004](#brb31132-bib-0033){ref-type="ref"}; Matsuzaki, Honkura, Ellis‐Davies, & Kasai, [2004](#brb31132-bib-0039){ref-type="ref"}). The long‐term effect in this meta‐analysis may be similar with the theory of Cohen et al. ([2018](#brb31132-bib-0009){ref-type="ref"}) concerning maintenance treatment that discontinuous treatment will reduce the effect of treatment, the maintenance treatment is a routine treatment for electroshock treatment.

The differences in long‐term effects of these studies may be due to the following reasons. In this current analysis, Khedr et al. ([2003](#brb31132-bib-0027){ref-type="ref"}) were included. In their study, the patients received no anti‐Parkinsonism medication for at least 1 month before the start of the study. This is different from the patients of other included studies. Also rTMS was applied for lower limbs and hand (right then left hemispheres) with the total numbers of 20,000 pulses. It produced greater effect size than most other studies. The result of this study may affect the reliability of the results in this analysis. However, when this study was removed, our meta‐analysis still showed significant results.

There are still limitations of this meta‐analysis. First, the experimental designs of the included studies were not homogenous (e.g., randomized controlled trials versus crossover design). Second, the selected participants varied in age, disease stage, and other biological characteristics that may have confounded the results, and third, non‐English studies were excluded in this meta‐analysis.

In conclusion, this meta‐analysis shows significant benefits of HF‐rTMS therapy over the M1 on motor signs of PD patients as measured by UPDRS‐III. Multi‐sessions of HF‐rTMS over the M1 (especially bilateral M1) with a total of 18,000--20,000 pulses appear to have produced the better efficacy.
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